Halia Therapeutics’ Ofirnoflast (HT-6184) Receives FDA Fast Track Designation for Lower-Risk MDS

BioUtah USA

Overview

Halia Therapeutics’ Ofirnoflast (HT-6184), an oral NEK7 allosteric modulator for lower-risk myelodysplastic syndromes (LR-MDS), has been granted FDA Fast Track designation. This decision follows promising Phase 2 data presented at EHA 2026, demonstrating durable transfusion independence and multi-lineage hematologic improvements. The designation is expected to accelerate the development and review process for this potential new treatment, which previously received Orphan Drug Designation.

In Depth

Key Findings

Halia Therapeutics announced that its investigational oral therapy, Ofirnoflast (HT-6184), for lower-risk myelodysplastic syndromes (LR-MDS), has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). This critical regulatory milestone signifies the FDA’s recognition of Ofirnoflast’s potential to address a serious unmet medical need and expedite its path to market for patients.

Technical / Clinical Details

Ofirnoflast is an oral allosteric modulator targeting NEK7 (NIMA-related kinase 7), representing a novel mechanism of action. Results from a Phase 2 clinical trial, presented at the European Hematology Association (EHA) 2026 Congress, showed encouraging efficacy and safety in LR-MDS patients. Specifically, the data highlighted durable transfusion independence (TI) and multi-lineage hematologic improvements, suggesting a comprehensive benefit beyond red blood cell counts. Patients exhibited reduced reliance on transfusions, coupled with improvements across various blood cell lines. The drug’s oral formulation offers a significant advantage in terms of patient convenience and adherence compared to existing injectable therapies. Ofirnoflast was also previously granted Orphan Drug Designation by the FDA, underscoring its potential for rare disease treatment.

Background & Context

LR-MDS is a chronic hematologic malignancy characterized by ineffective blood cell production, leading to severe anemia, thrombocytopenia, and neutropenia. Many patients require frequent red blood cell transfusions, which can lead to iron overload and diminished quality of life. Current treatment options for LR-MDS are limited, and there is a high unmet need for novel, effective, and less burdensome therapies. The Fast Track designation facilitates closer interaction with the FDA, allows for rolling review of the marketing application, and potentially qualifies the therapy for accelerated approval, all designed to bring important new drugs to patients sooner.

Strategic Significance & Outlook

The Fast Track designation is a strategic advantage for Halia Therapeutics, enabling more efficient and expedited clinical development. This will allow for more frequent communication with the FDA, which can lead to faster resolution of potential regulatory issues and a streamlined pathway towards regulatory submission. The company plans to continue advancing Ofirnoflast through further clinical trials to build a robust evidence base for its efficacy and safety. If successful, Ofirnoflast has the potential to significantly impact the treatment landscape for LR-MDS, offering a much-needed oral option that could improve patient outcomes and quality of life.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime